In its UDRHP-I filing to Sebi, the company any ‘adverse’ outcome in legal proceedings involving Zostel may materially and adversely affect its business, reputation, prospects, results of operation and financial condition, including potential issuance or transfer of up to 7% of its shareholding.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.